|
1
|
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman
M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C,
et al: Heart disease and stroke statistics-2017 update: A report
from the american heart association. Circulation. 135:e146–e603.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mishra PK, Ying W, Nandi SS, Bandyopadhyay
GK, Patel KK and Mahata SK: Diabetic cardiomyopathy: An
immunometabolic perspective. Front Endocrinol (Lausanne). 8:722017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gersh BJ, Sliwa K, Mayosi BM and Yusuf S:
Novel therapeutic concepts: The epidemic of cardiovascular disease
in the developing world: Global implications. Eur Heart J.
31:642–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aneja A, Tang WH, Bansilal S, Garcia MJ
and Farkouh ME: Diabetic cardiomyopathy: Insights into
pathogenesis, diagnostic challenges, and therapeutic options. Am J
Med. 121:748–757. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shivalkar B, Dhondt D, Goovaerts I, Van
Gaal L, Bartunek J, Van Crombrugge P and Vrints C: Flow mediated
dilatation and cardiac function in type 1 diabetes mellitus. Am J
Cardiol. 97:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carugo S, Giannattasio C, Calchera I,
Paleari F, Gorgoglione MG, Grappiolo A, Gamba P, Rovaris G, Failla
M and Mancia G: Progression of functional and structural cardiac
alterations in young normotensive uncomplicated patients with type
1 diabetes mellitus. J Hypertens. 19:1675–1680. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pappachan JM, Varughese GI, Sriraman R and
Arunagirinathan G: Diabetic cardiomyopathy: Pathophysiology,
diagnostic evaluation and management. World J Diabetes. 4:177–189.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karp X and Ambros V: Developmental
biology. Encountering microRNAs in cell fate signaling. Science.
310:1288–1289. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allegra A, Alonci A, Campo S, Penna G,
Petrungaro A, Gerace D and Musolino C: Circulating microRNAs: New
biomarkers in diagnosis, prognosis and treatment of cancer
(review). Int J Oncol. 41:1897–1912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sayed D and Abdellatif M: MicroRNAs in
development and disease. Physiol Rev. 91:827–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shan ZX, Lin QX, Deng CY, Zhu JN, Mai LP,
Liu JL, Fu YH, Liu XY, Li YX, Zhang YY, et al: miR-1/miR-206
regulate Hsp60 expression contributing to glucose-mediated
apoptosis in cardiomyocytes. FEBS Lett. 584:3592–3600. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu H, Buchan RJ and Cook SA: Microrna-223
regulates glut4 expression and cardiomyocyte glucose metabolism.
Cardiovasc Res. 86:410–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horie T, Ono K, Nishi H, Iwanaga Y, Nagao
K, Kinoshita M, Kuwabara Y, Takanabe R, Hasegawa K, Kita T and
Kimura T: MicroRNA-133 regulates the expression of GLUT4 by
targeting KLF15 and is involved in metabolic control in cardiac
myocytes. Biochem Biophys Res Commun. 389:315–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B,
Zhang Y, Xu C, Bai Y, Wang H, et al: The muscle-specific microRNA
miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1
and KCNJ2. Nat Med. 13:486–491. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen JF, Mandel EM, Thomson JM, Wu Q,
Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of
microRNA-1 and microRNA-133 in skeletal muscle proliferation and
differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhong D, Huang G, Zhang Y, Zeng Y, Xu Z,
Zhao Y, He X and He F: MicroRNA-1 and microRNA-206 suppress
LXRalpha-induced lipogenesis in hepatocytes. Cell Signal.
25:1429–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao G, Liang Y, Broderick CL, Oldham BA,
Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, et al:
Antidiabetic action of a liver × receptor agonist mediated by
inhibition of hepatic gluconeogenesis. J Biol Chem. 278:1131–1136.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N,
Anghel A, Lutfy K and Friedman TC: Liver X receptor agonist
T0901317 inhibition of glucocorticoid receptor expression in
hepatocytes may contribute to the amelioration of diabetic syndrome
in db/db mice. Endocrinology. 147:5061–5068. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cannon MV, Silljé HHW, Sijbesma JWA, Khan
MAF, Steffensen KR, van Gilst WH and de Boer RA: LXRα improves
myocardial glucose tolerance and reduces cardiac hypertrophy in a
mouse model of obesity-induced type 2 diabetes. Diabetologia.
59:634–643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi D and Young LH: AMPK: Energy sensor and
survival mechanism in the ischemic heart. Trends Endocrinol Metab.
26:422–429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumarapeli AR and Wang X: Genetic
modification of the heart: Chaperones and the cytoskeleton. J Mol
Cell Cardiol. 37:1097–1109. 2004.PubMed/NCBI
|
|
24
|
Renault TT, Teijido O, Antonsson B, Dejean
LM and Manon S: Regulation of Bax mitochondrial localization by
Bcl-2 and Bcl-x(L): Keep your friends close but your enemies
closer. Int J Biochem Cell Biol. 45:64–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He Q, Pu J, Yuan A, Yao T, Ying X, Zhao Y,
Xu L, Tong H and He B: Liver X receptor agonist treatment
attenuates cardiac dysfunction in type 2 diabetic db/db mice.
Cardiovasc Diabetol. 13:1492014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tarquini R, Lazzeri C, Pala L, Rotella CM
and Gensini GF: The diabetic cardiomyopathy. Acta Diabetol.
48:173–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rubler S, Dlugash J, Yuceoglu YZ, Kumral
T, Branwood AW and Grishman A: New type of cardiomyopathy
associated with diabetic glomerulosclerosis. Am J Cardiol.
30:595–602. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J,
Li K, Yu B, Li Z, Wang R, et al: Circulating microRNA-1 as a
potential novel biomarker for acute myocardial infarction. Biochem
Biophys Res Commun. 391:73–77. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fichtlscherer S, Zeiher AM and Dimmeler S:
Circulating microRNAs: Biomarkers or mediators of cardiovascular
diseases? Arterioscler Thromb Vasc Biol. 31:2383–2390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Townley-Tilson WHD, Callis TE and Wang D:
MicroRNAs 1, 133, and 206: Critical factors of skeletal and cardiac
muscle development, function, and disease. Int J Biochem Cell Biol.
42:1252–1255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng B, Cao Y, Chen S, Ruiz M and
Chakrabarti S: Reprint of: miRNA-1 regulates endothelin-1 in
diabetes. Life Sci. 118:275–280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX,
Lin SG and Li Y: Glucose induces apoptosis of cardiomyocytes via
microRNA-1 and IGF-1. Biochem Biophys Res Commun. 376:548–552.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu L, Yu H, Li X, Jin C, Zhao Y, Xu S and
Sheng X: P38 MAPK/miR-1 are involved in the protective effect of
EGCG in high glucose-induced C×43 downregulation in neonatal rat
cardiomyocytes. Cell Biol Int. 40:934–942. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhai C, Tang G, Peng L, Hu H, Qian G, Wang
S, Yao J and Zhang X, Fang Y, Yang S and Zhang X: Inhibition of
microRNA-1 attenuates hypoxia/re-oxygenation-induced apoptosis of
cardiomyocytes by directly targeting Bcl-2 but not GADD45Beta. Am J
Transl Res. 7:1952–1962. 2015.PubMed/NCBI
|
|
35
|
Adams JM: Ways of dying: Multiple pathways
to apoptosis. Genes Dev. 17:2481–2495. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pawlowski J and Kraft AS: Bax-induced
apoptotic cell death. Proc Natl Acad Sci USA. 97:529–531. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pena-Blanco A and Garcia-Saez AJ: Bax, bak
and beyond-mitochondrial performance in apoptosis. FEBS J.
285:416–431. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brown LM, Hanna DT, Khaw SL and Ekert PG:
Dysregulation of BCL-2 family proteins by leukemia fusion genes. J
Biol Chem. 292:14325–14333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma Z, Deng C, Hu W, Zhou J, Fan C, Di S,
Liu D, Yang Y and Wang D: Liver × receptors and their agonists:
Targeting for cholesterol homeostasis and cardiovascular diseases.
Curr Issues Mol Biol. 22:41–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fessler MB: The challenges and promise of
targeting the liver × receptors for treatment of inflammatory
disease. Pharmacol Ther. 181:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Parikh M, Patel K, Soni S and Gandhi T:
Liver X receptor: A cardinal target for atherosclerosis and beyond.
J Atheroscler Thromb. 21:519–531. 2014.PubMed/NCBI
|
|
43
|
Ceroi A, Masson D, Roggy A, Roumier C,
Chague C, Gauthier T, Philippe L, Lamarthee B, Angelot-Delettre F,
Bonnefoy F, et al: LXR agonist treatment of blastic plasmacytoid
dendritic cell neoplasm restores cholesterol efflux and triggers
apoptosis. Blood. 128:2694–2707. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cao G, Bales KR, DeMattos RB and Paul SM:
Liver X receptor-mediated gene regulation and cholesterol
homeostasis in brain: Relevance to Alzheimer's disease
therapeutics. Curr Alzheimer Res. 4:179–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Traversari C, Sozzani S, Steffensen KR and
Russo V: LXR-dependent and -independent effects of oxysterols on
immunity and tumor growth. Eur J Immunol. 44:1896–1903. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Calkin AC and Tontonoz P: Transcriptional
integration of metabolism by the nuclear sterol-activated receptors
LXR and FXR. Nat Rev Mol Cell Biol. 13:213–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Im SS and Osborne TF: Liver × receptors in
atherosclerosis and inflammation. Circ Res. 108:996–1001. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee HJ, Ryu JM, Jung YH, Lee SJ, Kim JY,
Lee SH, Hwang IK, Seong JK and Han HJ: High glucose upregulates
BACE1-mediated Aβ production through ROS-dependent HIF-1α and
LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells.
Sci Rep. 6:367462016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ou Z, Wada T, Gramignoli R, Li S, Strom
SC, Huang M and Xie W: MicroRNA hsa-miR-613 targets the human
LXRalpha gene and mediates a feedback loop of LXRalpha
autoregulation. Mol Endocrinol. 25:584–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Laffitte BA, Repa JJ, Joseph SB, Wilpitz
DC, Kast HR, Mangelsdorf DJ and Tontonoz P: LXRs control
lipid-inducible expression of the apolipoprotein E gene in
macrophages and adipocytes. Proc Natl Acad Sci USA. 98:507–512.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Venkateswaran A, Repa JJ, Lobaccaro JM,
Bronson A, Mangelsdorf DJ and Edwards PA: Human white/murine ABC8
mRNA levels are highly induced in lipid-loaded macrophages. A
transcriptional role for specific oxysterols. J Biol Chem.
275:14700–14707. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Repa JJ, Turley SD, Lobaccaro JA, Medina
J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM and Mangelsdorf
DJ: Regulation of absorption and ABC1-mediated efflux of
cholesterol by RXR heterodimers. Science. 289:1524–1529. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Laffitte BA, Joseph SB, Chen M, Castrillo
A, Repa J, Wilpitz D, Mangelsdorf D and Tontonoz P: The
phospholipid transfer protein gene is a liver X receptor target
expressed by macrophages in atherosclerotic lesions. Mol Cell Biol.
23:2182–2191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jiang XC, Beyer TP, Li Z, Liu J, Quan W,
Schmidt RJ, Zhang Y, Bensch WR, Eacho PI and Cao G: Enlargement of
high density lipoprotein in mice via liver × receptor activation
requires apolipoprotein e and is abolished by cholesteryl ester
transfer protein expression. J Biol Chem. 278:49072–49078. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mak PA, Kast-Woelbern HR, Anisfeld AM and
Edwards PA: Identification of PLTP as an LXR target gene and apoE
as an FXR target gene reveals overlapping targets for the two
nuclear receptors. J Lipid Res. 43:2037–2041. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Javitt NB: Cholesterol,
hydroxycholesterols, and bile acids. Biochem Biophys Res Commun.
292:1147–1153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Niesor EJ, Flach J, Lopes-Antoni I, Perez
A and Bentzen CL: The nuclear receptors FXR and LXRalpha: Potential
targets for the development of drugs affecting lipid metabolism and
neoplastic diseases. Curr Pharm Des. 7:231–259. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jianhua L, Xueqin M and Jifen H:
Expression and clinical significance of LXRα and SREBP-1c in
placentas of preeclampsia. Open Med (Wars). 11:292–296.
2016.PubMed/NCBI
|
|
59
|
Harasiuk D, Baranowski M, Zabielski P,
Chabowski A and Górski J: Liver × receptor agonist to901317
prevents diacylglycerols accumulation in the heart of
streptozotocin-diabetic rats. Cell Physiol Biochem. 39:350–359.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Laffitte BA, Chao LC, Li J, Walczak R,
Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ,
Collins JL, et al: Activation of liver X receptor improves glucose
tolerance through coordinate regulation of glucose metabolism in
liver and adipose tissue. Proc Natl Acad Sci USA. 100:5419–5424.
2003. View Article : Google Scholar : PubMed/NCBI
|
